Adherence Assessment for Supplements
Small Business Information
CALDERA PHARMACEUTICALS, INC.
278 DP Road Suite D, LOS ALAMOS, NM, 87544
AbstractDESCRIPTION (provided by applicant): Caldera Pharmaceuticals uses protein fractionation techniques and XRpro technology to determine protein CAM/metabolite binding as a means to determine adherence to CAM regimens in NCCAM clinical trials. Caldera will us e their high-throughput proteomics technology to identify CAM Adherence Biomarkers (CABs) using our unique, national award winning XRpro technology. Caldera, in collaboration with Los Alamos National Laboratory, developed XRpro. This technology allows the identification and measurement of CAM adherence by measuring CABs consisting of protein-ligand adducts and protein-metal metabolites with no a priori knowledge of which proteins are involved. Therefore, antibodies to specific proteins or specific protein a ssays are not required. Caldera Pharmaceuticals has 2000 square feet of lab space and 1800 square feet of office space. This area is well equipped for chemical and biological RandD. Equipment available for this work includes: fume hoods, sterilization oven s, reaction glassware, rotary evaporator, vacuum lines for reactions and distillations, atmosphere controlled glove boxes, heating/stirring mantles, spectrometers (UV-VIS-NIR), NMR, crystallography, fluorimeters, FTIR, TGA and DSC, microscopes, a customize d EDAX Eagle III MXRF spectrometer and a customized EDAX Eagle II MXRF spectrometer and Horiba XGT 5000 XRF microscope, and a custom-built confocal XRF microscope, FPLC, and an Applied Biosystems Voyager-DE STR MALDI-TOF and QSTAR XL MS/MS mass spectromete r. Caldera has access to machine and electronics shops. Caldera facilities meet environmental laws and regulations of federal, state, and local governments relating to: airborne emissions, waterborne effluents, external radiation levels, outdoor noise, sol id and bulk waste disposal practices, and handling and storage of toxic and hazardous materials.
* information listed above is at the time of submission.